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Background: The classification of pain into nociceptive and neuropathic pain is based on characteristic symptoms
and different pathophysiological mechanisms. In a recent investigation, we found a disrupted TH17/Treg balance in
patients suffering from chronic unspecific low back pain (CLBP). These patients did not show any signs of neuropathy.
There is evidence for a considerable impact of the immune system also in neuropathic pain. However, the role of the
adaptive immune system is still unclear. In the present study, we investigated systemic T-cell subset responses and
T-cell related cytokine profiles in patients with chronic neuropathic pain.
Methods: We analyzed T-cell subsets, mRNA expression and T-cell-related cytokine profiles in 26 patients suffering
from neuropathic pain in comparison to 26 healthy controls. Using multicolor flow cytometry (FACS), we quantified the
number of T helper cells 1 (TH1), TH2, TH17 and regulatory T-cells (Tregs). Forkhead-Box-Protein 3 (FoxP3), Transforming
growth factor-β (TGF-β) and RAR-related orphan receptor-γT (ROR-γT) mRNA expression was determined by
quantitative real-time PCR (qPCR) and levels of pain-related cytokines were measured by Human Cytokine Multiplex
Immunoassay (Macrophage inflammatory protein-1α (MIP-1α), Tumor necrosis factor-α (TNF-α), Interferon-γ (IFN-γ),
Interleukin (IL) -4, IL-6, IL-10, IL-17, and IL-23).
Results: We found a TH17/Treg imbalance with significantly increased anti-inflammatory Tregs and decreased
pro-inflammatory TH17 cells in patients with neuropathic pain as compared to healthy controls. These results
were confirmed on mRNA level: Treg-related FoxP3 and TGF-β mRNA expression was elevated, whereas expression
of TH17-related RORγT was reduced. Cytokine analyses revealed only marginal changes.
Conclusions: Our investigation revealed a clear shift of T-cell subsets towards anti-inflammation in patients with
neuropathic pain. Interestingly, this is quite similar to our previous findings in CLBP patients, but even more
pronounced. Therefore, it remains to be elucidated in future investigations whether the immune changes represent
an underlying pathophysiological mechanism or an epiphenomenon induced by ongoing pain and stress.
German Clinical Trial Register (DRKS): Trial registration number: DRKS00005954
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Neuropathic pain represents a major problem in clinical
practice. In contrast to nociceptive pain, which is caused
by damage or potential damage to tissue, neuropathic
pain occurs due to a lesion or disease of the peripheral
or central nervous system. It is characterized by burning
and lancinating pain sensations and further somatosensory
disturbances like hypo- and hypersensitivity. Very often,
neuropathic pain is more difficult to treat and more
refractory to common analgesics, including non-steroidal* Correspondence: benjamin.luchting@med.uni-muenchen.de
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unless otherwise stated.anti-inflammatory drugs and opioids, than nociceptive
pain [1,2]. Despite extensive research, the underlying
pathophysiological mechanisms of neuropathic pain are
still not fully understood. In recent years, increasing
evidence indicates a pivotal role of the immune system
in neuropathic pain [3,4]. The majority of previously
published data link pain syndromes with higher levels
of pro-inflammatory cytokines. Due to these findings,
attempts were made in numerous studies to reduce
neuropathic pain by blocking pro-inflammatory or enhan-
cing anti-inflammatory immune cells and cytokines [3].
For example, in animal models of neuropathy, tumor
necrosis factor-α (TNF-α), Interleukin (IL) -6, IL-17 andal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reduced pain hypersensitivity [5-9]. Comparable results
were obtained by increasing the anti-inflammatory cyto-
kines IL-4, IL-10 or Transforming growth factor-β (TGF-β)
[10-12]. Nevertheless, despite those promising experimental
findings, there are no pharmacological agents available
for the specific immunological therapy of neuropathic
pain until now.
Cytokines and neutrophils are important during the
early stages of acute pain, whereas T-lymphocytes seem
to play a central role in chronic neuropathic pain [13].
Regarding T-cells as key players of the adaptive immune
system, a TH1/TH2 imbalance has already been shown
in patients with complex regional pain syndrome (CRPS)
and chronic pelvic pain [14,15]. In recent years, TH1/
TH2 dichotomy has been extended by the identification
of two other CD4+ T-cell lineages: TH17 and regulatory
T-cells (Tregs) [16]. TH17 cells appear to be the key
effector T-cells in a variety of human autoimmune
diseases and Tregs play a vital role in controlling adap-
tive immune responses. In neuropathy, TH17 has been
linked to increased pain sensitivity and destructive effects
promoting persistent pain [16], while Tregs were found
to be mainly involved in the endogenous recovery [17].
Recently published data showed an increased proportion
of Tregs in patients with postherpetic neuralgia [18].
Assuming a beneficial role for an anti-inflammatory T-cell
shift, a phase one trial was carried out with an anti-CD28
antibody, preferentially expanding TH2 cells and Tregs in
human volunteers. Despite promising results in several
animal models, the clinical trial had to be cancelled
because of severe side effects [19]. In patients with
neuropathic pain, the role of T-cell subsets has not yet
been investigated.
In a recent study, we found that patients suffering
from nociceptive, non-specific chronic low back pain
(CLBP), without any signs of neuropathic pain compo-
nents, display a clear disruption of the TH17/Treg balance
as compared to healthy volunteers [20]. Since clinical and
pathophysiological mechanisms differ considerably between
nociceptive and neuropathic pain, we aimed to detail
changes of pro- and anti-inflammatory T-cell subsets
and the respective relative mRNA expression, as well as
pain-related cytokine levels in patients with chronic neuro-
pathic pain in comparison to pain free controls. While the
cytokine measurement did not reveal any relevant results,
we found a distinct anti-inflammatory shift of the T-cell
subsets and their respective mRNA expression.
Methods
Ethics statement
The study followed the principles of the Declaration of
Helsinki and was approved by the Ethics Committee
of the Ludwig Maximilians University Munich (Ethicalapproval number: 331–10). This study was registered
on German Clinical Trial Register (Trial registration:
DRKS00005954).Subjects
Patient recruitment of our prospective study was esti-
mated to last for two years. All patients presented to our
Department of Anesthesiology and Pain Medicine, Ludwig-
Maximilians University Munich with neuropathic pain for
at least six months were assessed for fulfillment of the
inclusion criteria and asked for their consent to participate
in the study. In addition, healthy pain-free volunteers
without any signs or history of pain were asked for their
participation. Neuropathic pain was diagnosed according
to its international definition: ‘pain caused by a lesion
or disease of the somatosensory nervous system’ [2], by
pain history, physical examination and the PainDETECT
questionnaire.
This questionnaire consists of several items related to
neuropathic symptoms (burning sensations, tingling or
prickling sensations, shooting or lancinating, hyperalge-
sia, dysesthesia, allodynia or paresthesia) with excellent
sensitivity (85%) and specificity (80%) [21]. Additionally,
quantitative sensory testing (QST) was performed in all
patients according to the protocol of the German Research
Group on neuropathic pain [22]. Patients with mixed pain
(nociceptive and neuropathic components) like complex
regional pain syndrome (CRPS) and low back pain with
radiculopathy were excluded. Further exclusion criteria
were autoimmune, chronic systemic, inflammatory, neo-
plastic or psychiatric diseases, as well as drug abuse and
pregnancy. Patients taking any current medication with
opioids, non-opioids or co-analgesics were excluded. None
of the patients had been treated with corticosteroids or
had received immunomodulatory agents currently or in
the past. Any signs of acute inflammatory disease were
disclosed by laboratory examination, including plasma
concentration of C-reactive protein (CRP), total and dif-
ferential leucocyte count, as well as measurement of the
body temperature. Patients rated their recalled average
pain intensity using an 11-point numerical rating scale
(NRS): 0 meaning ‘no pain’ and 10 meaning ‘worst pain
imaginable’.
Self-perceived stress was evaluated using the German
version of the Questionnaire for Actual Demands (KAB:
Kurzfragebogen zur aktuellen Beanspruchung) in patients
and healthy volunteers. The KAB was designed to repeat-
edly quantify an individual’s acute or chronic stress. It
is highly sensitive to short-term or situational changes
during a stressful experience. The rating is based on a
six-point scale ranging from one to six based on normal-
ized adjectives. Higher KAB values indicate increased
perceived levels of stress [23].
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Samples of peripheral blood from all patients and healthy
controls were collected between 9:00 and 9:30 am, centri-
fuged at 2000 × g/10 min and stored in polypropylene
aliquot tubes at −80°C. Samples were then assessed for
levels of T-cell-related cytokines using a human cytokine
multiplex immunoassay (Myriad Rules-Based Medicine
Inc., Austin, Texas, United States). The multiplex micro-
bead assay is based on Luminex technology and measures
proteins in a similar manner to standard sandwich ELISA,
with comparable sensitivity and range. Regarding the detec-
tion limits, the lower limit of quantitation (LLOQ) for the
cytokines were: MiP1-α: 42.0 pg/ml, TNF-α: 23.0 pg/ml,
IFN-γ: 1.5 pg/ml, IL-4: 29.0 pg/ml, IL-6: 11.0 pg/ml, IL-10:
6.9 pg/ml, IL-17: 4.0 pg/ml, and IL-23: 0.59 pg/ml. The
LLOQ is the lowest concentration of an analyte in a sample
that can be reliably detected and at which the total error
meets the laboratory’s requirements for accuracy [24].
Flow cytometric staining and analysis
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated by density gradient preparation over Ficoll-Uropoline
(Sigma Aldrich, Taufkirchen, Germany) of all heparinized
venous blood samples. Then, PBMCs were cryopreserved
in Roswell Park Memorial Institute medium (RPMI)
freezing media (Sigma Aldrich, Taufkirchen, Germany),
containing 10% Fetal calf serum (FCS), (Sigma Aldrich,
Taufkirchen, Germany) and 10% Dimethyl sulfoxide
(DMSO), (Sigma Aldrich, Taufkirchen, Germany) [25],
and stored at −30°C for 24 hours, and then at −196°C
until measurement. After storage, samples were thawed
rapidly and washed twice to eliminate DMSO. For TH1,
TH2 and TH17 analysis, cells were stimulated for five
hours with cell stimulation cocktail, including protein
transport inhibitors Phorbol 12-myristate 13-acetate
(PMA), ionomycin, Brefeldin A and monensin (eBio-
science, San Diego, California, United States), according
to the manufacturer’s protocol. Subsequently, cells were
extracellularly stained with anti-human CD4 antibody and
consecutively fixed and permeabilized (Fix-Perm-Solutions
A and B, Life Technologies, Darmstadt, Germany) for
intracellular staining with anti-human Interferon-γ, Inter-
leukin (IL) -4 and IL-17 antibody (Biolegend, San Diego,
California, United States). T-cell distribution was measured
by fluorescent-activated cell sorting (FACS) analysis with
the Attune Acoustic Focusing Cytometer (Life Technolo-
gies, Carlsbad, United States), and exemplary pictures of
the gating strategy for TH17 cells are displayed in Figure 1
and Additional files 1 and 2. Tregs were identified and
quantified after surface staining of PBMCs with monoclonal
antibodies (mAbs) specific for anti-human CD4, CD25 and
CD127 and intracellular staining with an anti-human
FoxP3 antibody (Biolegend, San Diego, California, United
States). The frequencies of CD4+CD25high T-cells andCD4+CD25highCD127lowFoxP3+ T-cells were expressed as
percentage of total CD4+ T-cells by sequential gating on
lymphocytes. Exemplary pictures of the gating strategy
for Tregs are displayed in Figure 2 and Additional files 1
and 2. Isotype controls (Biolegend, San Diego, California,
United States) were given for compensation and confirm-
ation of antibody specificity.
Quantitative real-time PCR (qPCR)
CD4+ cells were isolated from PBMCs by magnetic
separation with Whole Blood CD4 MicroBeads (MACS
Miltenyi Biotec, Auburn, California, United States) accord-
ing to the manufacturer’s recommendations. Subsequently,
total RNA was isolated using the mirVana miRNA Isolation
Kit followed by a DNase-digest with Turbo DNA-free Kit
(Ambion, Darmstadt, Germany). Quantity and purity of the
isolated RNA were measured using a NanoDrop ND-1000
spectrophotometer (Peqlab, Erlangen, Germany). After
amplification of total RNA using TargetAmp 1-Round
aRNA Amplification Kit (Epicentre Biotechnologies,
Madison, Wisconsin, United States) and purification using
RNeasy Mini Kit (Qiagen, Hilden, Germany), cDNA syn-
thesis was performed with SuperScript III First Strand
Synthesis System (Invitrogen, Darmstadt, Germany) and
random hexamers (Qiagen, Hilden, Germany). Quantitative
RT-PCR was performed in duplicates with the LightCycler
480 instrument (Roche Diagnostics, Mannheim, Germany)
using LightCycler 480 Probes Master and RealTime ready
single assays (Roche Diagnostics, Mannheim, Germany)
and UniversalProbeLibrary (UPL) probes. The Real-
Time ready single assays contain target-specific primers
and a UPL-LNA probe (Roche Diagnostics, Mannheim,
Germany). Primer sequences and qPCR characteristics
are given in Table 1. The cycling conditions comprised
an initial denaturation phase at 95°C for 10 minutes,
followed by 45 cycles at 95°C for 10 seconds, 60°C for
30 seconds and 72°C for one second. Relative mRNA
expression of FoxP3, TGF-β and RORγT was calculated
by Relative Quantification Software (Roche Diagnostics,
Mannheim, Germany) using an efficiency-corrected algo-
rithm with standard curves and reference gene normal-
ization against the reference genes succinate dehydrogenase
complex subunit A (SDHA) and TATA box binding protein
(TBP) as described in Ledderose et al. [26].
Statistical analyses
Statistical analyses were performed using SigmaStat 12.0
(Systat Software, Chicago, United States). Every statistical
analysis was started with testing for normal distribu-
tion using the Shapiro-Wilk test. Testing for differences
between groups was accomplished by the T-test for all
data with normal distribution and the nonparametric
Mann–Whitney rank sum test for all data without normal
distribution. Family-wise error rate was controlled at a
Figure 1 Gating strategy for the detection of pro-inflammatory TH17 cells. PBMCs were stained with Brilliant Violet (BV421)-labeled anti-human
IL-17 antibody. Lymphocyte population was gated from PBMCs according to forward scatter (FSC) characteristics and side scatter (SSC) characteristics
(see Figure 2) and then separated in IL-17 + TH17 cells. Representative results of a healthy control with a higher number of TH17 cells (A) and a patient
suffering from neuropathic pain with less TH17 cells (B) are shown. TH, T helper cells; PBMC, Peripheral blood mononuclear cells; IL, Interleukin.
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accordingly following the Benjamini-Hochberg algorithm.
P <0.05 were considered to be statistically significant.




Within two years of recruitment, 26 patients fulfilling the
inclusion criteria and 26 healthy controls were enrolled.
The characteristics of the participating patients and pain
syndromes are given in Table 2.
Granulocytes and lymphocytes were only slightly
changed in neuropathic pain
Venous blood was drawn between 9:00 and 9:30 am into
vacutainers containing Ethylenediaminetetraacetic acid
(EDTA) for routine laboratory studies. Upon analyzing
the number of neutrophil granulocytes, representing an
essential part of the innate immune system, as well as
lymphocytes, we found only slight alterations in patients
with neuropathic pain (neutrophils: 55.4 ± 9.1% in con-
trols versus 58.6 ± 9.3% in neuropathic pain, P = 0.268;
lymphocytes: 33.8 ± 8.1% in controls versus 29.2 ± 8.2%
in neuropathic pain, P = 0.069, Table 3).
Cytokine measurement did not reveal relevant results
The specific functions of T-cell subsets are based on their
respective cytokine release. TH1 cells produce predomin-
antly pro-inflammatory cytokines such as IFN-γ and
TNF-α, which support cellular immunity, whereas TH2
cells release anti-inflammatory cytokines, including IL-4and IL-10, which mediate humoral immunity. TH17
cells particularly produce the potent pro-inflammatory
cytokine IL-17, which is involved in many inflammatory
conditions. IL-23 is a key cytokine in the control of
inflammation in peripheral tissues, which stimulates
naïve CD4 T-cells to differentiate into TH17 cells, in
conjunction with IL-6 and TGF-β. Tregs have an anti-
inflammatory role by releasing anti-inflammatory cyto-
kines like IL-10 and TGF-β. However, it seems likely, that
TH1 and TH17 cytokines are central to increased pain
sensitivity, whereas TH2 and Treg derived cytokines may
be protective.
Therefore, we analyzed blood levels of pain-associated
and T-cell-related cytokines using human cytokine multi-
plex immunoassay (MIP-1α, TNF-α, IFN-γ, IL-4, IL-6,
IL-10, IL-17, and IL-23). Serum levels of IL-4, TNF-α
and IFN-γ were neither detectable in the peripheral blood
of patients nor in healthy controls. No differences between
patients and healthy controls were found analyzing IL-6,
IL-10 and IL-17. In accordance with numerous described
studies, serum levels of pro-inflammatory cytokines MIP-
1α and IL-23 were significantly higher in the peripheral
blood of patients suffering from neuropathic pain. How-
ever, it has to be noted that IL-23 was the only cytokine
with values above the so-called LLOQ, the lowest concen-
tration that can be reliably detected (see Methods section).
(IL-6: 1.2 ± 0.8 pg/ml in controls versus 2.5 ± 2.4 pg/ml in
neuropathic pain, P = 0.064; IL-10: 3.56 ± 2.45 pg/ml in
controls versus 3.69 ± 2.40 pg/ml in neuropathic pain,
P = 0.84; IL-17: 3.53 ± 2.11 pg/ml in controls versus
4.29 ± 2.02 pg/ml in neuropathic pain, P = 0.23; MIP-1α:
17.2 ± 11.2 pg/ml in controls versus 28.4 ± 16.4 pg/ml in
Figure 2 Gating strategy for the detection of the investigated Tregs. PBMCs were extracellularly stained with PerCP-labeled anti-human CD4-,
PE-labeled anti-CD25 antibody, Brilliant Violet (BV570)-labeled anti-CD127 antibody and intracellularly stained with Alexa Fluor (AF488)-labeled anti-human
FoxP3 antibody. Lymphocyte population was gated according to forward scatter (FSC) characteristics and side scatter (SSC) characteristics (A +D). Gated
lymphocytes were then separated in CD4 + CD25high cells (B + E) and CD4 + CD25highCD127lowFoxP3+ cells (C + F, named Treg). Representative
results of a healthy control (A-C) and a patient with neuropathic pain (D-F) are shown. Regulatory T-cells, Tregs; PBMC, Peripheral blood
mononuclear cells; Forkhead-Box-Protein 3, FoxP3.
Table 1 RT-PCR assay characteristics and primer
sequences
Gene Primer sequence
SDHA Roche RealTime Ready Single Assay ID 102136
TBP Roche RealTime Ready Single Assay ID 101145
FoxP3 Roche RealTime Ready Single Assay ID 113503
TGF-β for 5′ACTACTACGCCAAGGAGGTCAC 3′
rev 5′TGCTTGAACTTGTCATAGATTTCG 3′, UPL probe #31
RORγT for 5′CAGCGCTCCAACATCTTCT 3′
rev 5′CCACATCTCCCACATGGAC 3′, UPL probe #69
Table 2 Patient characteristics
Item Healthy NeP (all) PNeP PHN OFP
Numbers (n) 26 26 13 7 6
Age 39 ± 11 56 ± 14* 49 ± 14* 71 ± 6* 53 ± 10*
Female 52% 73% 69% 71% 83%
BMI 23.4 ± 2.8 24.0 ± 3.4 25.1 ± 3.2 22.4 ± 3.4 23.6 ± 3.8
NRS (rest) 0.0 ± 0.0 4.5 ± 2.3* 4.3 ± 2.5* 3.7 ± 1.6* 5.6 ± 2.1*
NRS (motion) 0.0 ± 0.0 6.2 ± 2.7* 6.0 ± 2.3* 4.7 ± 3.9* 6.6 ± 3.3*
KAB 1.9 ± 0.7 3.2 ± 0.8* 3.3 ± 0.7* 2.9 ± 1.1* 3.1 ± 0.8*
NeP (all): all patients suffering from neuropathic pain; PNeP: Peripheral
neuropathic pain (symmetrical polyneuropathy/peripheral mononeuropathy);
PHN: postherpetic neuralgia; OFP: orofacial pain; NRS (rest/motion): Numeric
rating scale (0 to 10) of pain, 0: ‘no pain’ , 10: ‘worst pain imaginable’; KAB:
Questionnaire for self-perceived stress ranging from one (no stress) to six
(maximum stress). Results are expressed as mean ± standard deviation (SD),
*P <0.05 versus healthy controls.
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Table 3 Differential blood count, flow cytometric and RT-PCR results of patient subgroups
Item Healthy NeP (all) PNeP PHN OFP
Neutrophils (%) 55.4 ± 9.1 58.6 ± 9.3 57.5 ± 10.1 57.3 ± 9.0 62.3 ± 8.5
Lymphocytes (%) 33.8 ± 8.1 29.2 ± 8.2 30.5 ± 7.9 28.3 ± 9.6 27.2 ± 8.1
CD4+ Counts × 1000 28.7 ± 7.3 33.5 ± 15.4 36.8 ± 18.8 30.3 ± 15.3 30.8 ± 2.9
CD4+ (%) 43.4 ± 9.9 47.5 ± 11.9 49.9 ± 12.6 44.3 ± 13.8 46.6 ± 8.0
TH1 (%) 9.7 ± 4.7 9.6 ± 4.1 10.9 ± 4.7 7.2 ± 3.1 9.3 ± 2.7
TH2 (%) 1.3 ± 1.2 1.5 ± 0.8 1.7 ± 0.7 0.9 ± 0.5 2.0 ± 0.9
TH17 (%) 1.3 ± 1.0 0.7 ± 0.4* 0.9 ± 0.4 0.4 ± 0.1* 0.8 ± 0.5
RORγT 2.7 ± 1.4 1.9 ± 1.0 1.8 ± 0.6* 1.9 ± 1.2* 2.2 ± 1.5
CD4+CD25high (%) 3.7 ± 0.7 5.4 ± 1.5* 5.1 ± 1.8* 5.0 ± 0.7* 6.4 ± 0.9*
Tregs (%) 2.0 ± 1.0 3.9 ± 1.3* 3.5 ± 1.1* 4.0 ± 1.9* 4.4 ± 0.9*
FoxP3 0.6 ± 0.2 1.2 ± 0.8* 1.0 ± 0.7* 1.3 ± 0.3* 1.4 ± 1.3*
NeP (all): all patients suffering from neuropathic pain; PNeP: Peripheral neuropathic pain (symmetrical polyneuropathy/peripheral mononeuropathy);
PHN: postherpetic neuralgia; OFP: orofacial pain; Results are expressed as mean ± standard deviation (SD), *P <0.05 versus healthy controls.
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trols versus 1.2 ± 0.4 pg/ml in neuropathic pain, P = 0.022).
TH17 frequency was distinctly decreased in neuropathic pain
Although many studies have analyzed the role of TH17
cells in human autoimmune diseases, there are very limited
data on the role of TH17 cells in patients with neuropathic
pain. TH17 cells act as an important pro-inflammatory
component and have been shown to promote inflamma-
tion in a number of diseases. The proportion of TH17
cells is expressed as percentage of all T-cells. As shown
in Figure 3, the frequency of TH17 cells was evidentlyFigure 3 Reduced TH17 frequency in patients with neuropathic pain.
with anti-human IL-17 antibody after five hours of stimulation. The results sho
blood of patients suffering from neuropathic pain. In accordance with these r
factor RORγT was reduced, but did not reach significance. T helper cells, TH; P
orphan receptor-γT, ROR-γT; *P <0.05 versus healthy controls.decreased in the peripheral blood of patients suffering
from neuropathic pain. Affirming these results, the relative
mRNA expression of the TH17 cell-specific transcription
factor RORγT was reduced, but did not reach significance
(TH17 cells: 1.3 ± 1.0% in controls versus 0.7 ± 0.4% in
neuropathic pain, P = 0.046; relative RORγT mRNA expres-
sion: 2.7 ± 1.4 in controls versus 1.9 ± 1.0 in neuropathic
pain, P = 0.064; Figure 3).
Treg frequency was distinctly increased in neuropathic pain
Human regulatory T-cells play a vital role in controlling
the adaptive immune response and in maintaining self-Using a multicolor flow cytometer, PBMCs were intracellularly stained
w a significantly decreased frequency of TH17 cells in the peripheral
esults, the relative mRNA expression of the TH17 cell-specific transcription
eripheral blood mononuclear cells, PBMC; Interleukin, IL; RAR-related
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diseases and to limit chronic inflammatory and nervous
system disturbances. On the other hand, the strong Treg-
induced immune suppression also impairs beneficial
responses such as anti-tumor immunity [27,28]. However,
there were limited data analyzing the functional role of
Tregs in neuropathic pain, which therefore remained
to be investigated. We analyzed the number of Tregs
by flow cytometry, using two staining procedures;
classic extracellular staining with CD4+CD25high and
the more specific intra- and extracellular staining
procedure with CD4+CD25highCD127lowFoxP3+. We
defined CD4+CD25highCD127lowFoxP3+ T-cells as Tregs.
The prevalence of Tregs was expressed as a ratio of
CD4+CD25highCD127lowFoxP3+ T cells as a percentage
of CD4+ T-cells. Figure 3 shows a significantly increased
frequency of Tregs in patients with neuropathic pain as
compared to controls. To confirm the quantitative obser-
vations of the Treg frequency we also determined the
relative mRNA expression of the specific transcription
factor FoxP3 and TGF-β by quantitative real-time PCR
(qPCR). As shown on Figure 4, significantly increased
mRNA levels of FoxP3 and TGF-β were observed in
patients with neuropathic pain. These results were
consistent with the flow cytometric analyses (Tregs:
2.0 ± 1.0% in controls versus 3.9 ± 1.3% in neuropathic
pain, P = 0.007; relative FoxP3 mRNA expression:
0.6 ± 0.2 in controls versus 1.2 ± 0.8 in neuropathic
pain, P = 0.028; relative TGF-β mRNA expression:
0.15 ± 0.06 in controls versus 0.25 ± 0.15 in neuropathic
pain, P = 0.009; Figure 4).Figure 4 Increased Treg frequency in patients with neuropathic pain.
analyzed after intra- and extracellular staining procedure. CD4 + CD25highCD
increased frequency of Tregs in patients with neuropathic pain as compare
Treg frequency, the relative mRNA expression of the Treg-specific transcriptio
PCR (qPCR). Affirmatively, increased mRNA levels of FoxP3 and TGF-β were co
helper cell, TH; Forkhead-box-protein 3, FoxP3; Transforming growth factor-β,TH1/TH2 balance was only slightly altered in
neuropathic pain
In previous investigations, the ratio of TH1 and TH2 cells
was used to characterize immune responses in different
diseases. In the present study, a trend towards a decreased
TH1/TH2 ratio was observed, which, however, did not
reach significance (TH1/TH2: 16.1 ± 17.4 in controls ver-
sus 10.1 ± 10.0 in neuropathic pain, P = 0.56; Figure 5).TH17/Treg balance was markedly disrupted in
neuropathic pain
TH17 cells play an important pro-inflammatory role
whereas Tregs are strong immune suppressors. Therefore,
the balance between TH17 cells and Tregs, along with
TH1/TH2 balance, is an important factor in analyzing the
immune response. Our results regarding T-cell subsets
alone demonstrated markedly reduced pro-inflammatory
TH17 cells with simultaneous elevated anti-inflammatory
Tregs. Conclusively, as shown in Figure 5, the TH17/Treg
ratio was significantly lower in the peripheral blood of
patients compared to healthy controls. These results indi-
cate a clear anti-inflammatory T-cell shift in neuropathic
pain (TH17/Treg: 0.9 ± 1.1 in controls versus 0.2 ± 0.1 in
neuropathic pain, P <0.007; Figure 5).Discussion
Neuropathic pain is a severe and frequent condition
which affects up to 18% of the population [29]. The
pathophysiological mechanisms leading to chronification
of neuropathic pain are a major focus of interest, but areIn addition to the TH17 cell quantification, the number of Tregs was
127lowFoxP3+ were defined as Tregs. The results show a significantly
d to healthy controls. To confirm the quantitative observations of the
n factor FoxP3 as well as TGF-β was determined by quantitative real-time
nsistent with the flow cytometric analyses. Regulatory T-cell, Treg; T
TGF-β; *P <0.05 versus healthy controls.
Figure 5 Altered TH1/TH2 and TH17/Treg balances in patients with neuropathic pain. While the TH1/TH2 ratio was only slightly decreased,
the TH17/Treg balance was significantly enhanced in patients as compared to healthy controls. These results indicate a clear anti-inflammatory
T-cell shift in neuropathic pain. T helper cell, TH; Regulatory T-cell, Treg; *P <0.05 versus healthy controls.
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critical involvement of the innate and adaptive immune
system in the pathophysiology of chronification. Several
types of immune cells have been implicated in the patho-
genesis of neuropathic pain [3]. The innate immune
system has been shown to be important during the early
stages of acute pain, represented particularly by neutro-
phils [13]. Regarding chronification, T-lymphocytes, as key
players of the adaptive immune system, seem to be of
major importance [30,31]. Traditionally, it has been
suggested that neuropathic pain is associated with a
pro-inflammatory immune response. Therefore, mainly
anti-inflammatory treatments targeting cytokines and
immune cells have been evaluated in several animal
models of neuropathic pain [3]. In a recent study, neuro-
pathic pain induced by experimental autoimmune neuritis
was successfully attenuated by expanding Tregs [17]. In
humans, the first Treg-expanding tests were stopped
because of life-threatening side effects [19]. Nevertheless,
the modulation of T-cells is still the focus of intense
research [32].
In the present study, we analyzed the pain-related
cytokines MIP-1α, TNF-α, IFN-γ, IL-4, IL-6, IL-10, IL-17
and IL-23 in the peripheral blood of 26 patients with
neuropathic pain and compared the results with those of
26 healthy controls. We found that the serum levels of
IL-4, TNF-α and IFN-γ were below the detectable limit
and no differences were found regarding IL-6, IL-10 and
IL-17. Only the pro-inflammatory cytokines MIP-1α and
IL-23 were significantly higher in neuropathic pain. It
has to be noted though, that except for IL-23, values of all
cytokines measured were below the lowest concentrationof an analyte in a sample that can be reliably detected.
This shortcoming of serum cytokine measurements in
pain syndromes has also been described by other authors
[33]. Taken together, our results indicated that serum
cytokine levels alone are not sufficient to monitor the
adaptive immune response in neuropathic pain and led us
to analyze the cellular compartment.
By routine laboratory studies regarding the differential
leucocyte count, we found only an unchanged number of
neutrophil granulocytes and a slightly reduced number of
lymphocytes in the peripheral blood of patients with
neuropathic pain. Using multicolor flow cytometry, we
subsequently quantified the numbers of TH1, TH2,
TH17 and Treg cells in the peripheral blood of our
patients. Contrary to our initial assumption, we found
clear indications for an anti-inflammatory T-cell shift:
Pro-inflammatory TH17 cells were significantly decreased,
whereas anti-inflammatory Tregs were significantly in-
creased. Consequently, the corresponding TH17/Treg
ratio was distinctly shifted towards an anti-inflammatory
immune response. To confirm the quantitative observa-
tions of the TH17 and Treg frequency, we also determined
the relative mRNA expression of the TH17 cell-specific
transcription factor RORγT, as well as TGF-β and the
Treg-specific transcription factor FoxP3 by quantitative
real-time PCR. A diminished RORγT mRNA expression
was in line with the reduced number of TH17 cells, while
a notably elevated FoxP3 and TGF-β mRNA expression
confirmed the increased Treg frequency. Regarding patient
subgroups, we found no differences in respect of the
anti-inflammatory T-cell shift and mRNA expressions be-
tween patients suffering from orofacial pain, postherpetic
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(Table 3). The question arises whether the observed
changes are of clinical relevance, particularly in view of
the overall low portion of the specific T-cell subsets.
Furthermore, it would be interesting and relevant to
investigate whether the immune changes can also be
found in the affected tissue.
Our results are, at first glance, unexpected since the
majority of previously published data describes the
association between pain and ‘immune activation’ based
on investigations of TH1 and TH2 cells, as well as cyto-
kines. This previous TH1/TH2 paradigm has, however,
been revised and updated with the discovery of TH17 cells
and the more specific detection of Tregs. Our findings,
together with recently published data regarding various
T-cell subsets, point to a strong association between pain
and ‘immune suppression’. Interestingly, the T-cell response
in the present study is comparable with our recent findings
in patients with CLBP, who also presented with high pain
and stress levels, but had no signs of neuropathic pain
[20]. There is a general consensus that neuropathic and
nociceptive pain are distinct entities, although basic
research clearly reveals a huge overlap of underlying
pathophysiological mechanisms, including neurotransmit-
ters and cytokines [2]. Our results show for the first time
that in both neuropathic and nociceptive pain the adaptive
immune system is altered in the same anti-inflammatory
way. The context of chronic stress and immune suppres-
sion has been described for many years, although not
extensively with regard to TH17 cells and Tregs [34]. An
anti-inflammatory T-cell shift has been found in patients
with chronic mild depression or chronic fatigue syndrome
[35-37], and both disorders are frequently associated with
all types of chronic pain.
Concerning the cellular mechanisms, T-cell differenti-
ation mainly depends on the cytokine milieu of the
microenvironment, but other pathways have also been
shown to be involved. For example, the hypothalamic-
pituitary-adrenal axis mediates immune regulation through
binding of stress hormones like adrenocorticotropic hor-
mone or cortisol to their cognate receptors at the surface of
T-cells. Furthermore, the sympathetic nervous system is
known to induce immune dysregulation via adrenaline and
noradrenaline [38]. These processes in turn play an import-
ant role in negative emotional states, such as stress and
depression. Our patients with neuropathic pain also suf-
fered from stress and psychological burden as revealed by
the enhanced KAB values. We therefore hypothesize that
the altered immune responses in both of our studies might
reflect a particular chronic pain-related stress reaction
Conclusions
In summary, we found a TH17/Treg imbalance with
increased anti-inflammatory Tregs and decreased pro-inflammatory TH17 cells in patients with neuropathic
pain. These results are quite similar to our previous
findings in patients with nociceptive CLBP who did
not show any signs of neuropathy, but similar pain and
stress levels. Therefore, it remains to be clarified in
future studies whether the immune changes represent an
underlying pathophysiological mechanism or an epiphe-
nomenon induced by ongoing pain and stress.
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